Can switching drugs outsmart resistant breast cancer?

NCT ID NCT07646171

Recruiting now Disease control Sponsor: Tel-Aviv Sourasky Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the drug everolimus can help women with a common type of advanced breast cancer (HR-positive, metastatic) whose cancer has stopped responding to a similar drug called alpelisib. The trial will enroll 19 women and measure how many see their tumors shrink. Researchers hope the response rate will be higher than the 9.5% seen in a previous trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: everolimus (Afinitor) combined with endocrine therapy
What this could lead to: If it works, this could offer a new treatment option for women with HR+ metastatic breast cancer whose cancer has stopped responding to a PI3K inhibitor.
What could go wrong: This is a very small, early-phase study (19 participants) with no comparison group. The hoped-for benefit may not appear, and side effects of everolimus can include mouth sores, rash, and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HORMONE RECEPTOR POSITIVE BREAST CANCER

Contacts and locations

Locations

Ichilov-Sourasky Medical Center
RECRUITING

Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.